Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Feb 27, 2024; 16(2): 571-584
Published online Feb 27, 2024. doi: 10.4240/wjgs.v16.i2.571
Published online Feb 27, 2024. doi: 10.4240/wjgs.v16.i2.571
Figure 1 Flow chart of selecting studies for inclusion.
RCT: Randomized controlled trial; IBD: Inflammatory bowel disease.
- Citation: Zheng FY, Yang KS, Min WC, Li XZ, Xing Y, Wang S, Zhang YS, Zhao QC. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis. World J Gastrointest Surg 2024; 16(2): 571-584
- URL: https://www.wjgnet.com/1948-9366/full/v16/i2/571.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i2.571